scispace - formally typeset
Open AccessJournal ArticleDOI

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

Thanyanan Reungwetwattana, +4 more
- 01 Jan 2017 - 
- Vol. 103, pp 27-37
TLDR
The current clinical and preclinical data available for small molecule tyrosine kinase inhibitors for non-small cell lung cancers, along with a number of other potential therapeutic options, including antibodies and immunotherapy are reviewed.
About: 
This article is published in Lung Cancer.The article was published on 2017-01-01 and is currently open access. It has received 131 citations till now. The article focuses on the topics: Crizotinib & Tyrosine-kinase inhibitor.

read more

Citations
More filters
Journal ArticleDOI

Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices

Nathan A. Pennell, +3 more
TL;DR: The major guidelines recommending biomarker testing in NSCLC are discussed, as well the logistical challenges to applying these guidelines to patients withNSCLC both in the United States and worldwide.
Journal Article

An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Lu Shun
- 01 Jan 2010 - 
Journal ArticleDOI

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Toshio Fujino, +10 more
- 01 Oct 2019 - 
TL;DR: MET-TKIs inhibited the growth of cells with MET exon 14 mutations, and this finding should provide relevant clinical implication for treating patients with lung cancer harboring MET ex on 14 mutations.
Journal ArticleDOI

Drug resistance to targeted therapeutic strategies in non-small cell lung cancer

Wen-Juan Liu, +4 more
- 01 Feb 2020 - 
TL;DR: Two different resistance mechanisms in NSCLC targeted therapies are discussed, namely changes in the targeted oncogenes (on-target resistance) and changes in other related signaling pathways (off- target resistance) in tumor cells.
Journal ArticleDOI

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo, +11 more
- 20 Jun 2019 - 
TL;DR: In this study, nearly all MET IHC positive cases are negative for MET amplification or METex14 mutations, suggesting IHC appears to be an inefficient screen for these genomic changes.
References
More filters
Journal ArticleDOI

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, +27 more
- 21 Oct 2015 - 
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Journal ArticleDOI

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

Julie R. Brahmer, +24 more
- 08 Jul 2015 - 
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, +28 more
- 03 Apr 2015 - 
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Journal ArticleDOI

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Roy S. Herbst, +18 more
- 09 Apr 2016 - 
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson, +318 more
- 01 Jan 2014 - 
TL;DR: In this paper, the authors report molecular profiling of 230 resected lung adnocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses.
Related Papers (5)

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

Mark M. Awad, +12 more
- 04 Jan 2016 - 

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Garrett M. Frampton, +37 more
- 13 May 2015 - 

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paul K. Paik, +14 more
- 13 May 2015 - 

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Joanna H.M. Tong, +15 more
- 15 Jun 2016 - 

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

Xuewen Liu, +9 more
- 19 Sep 2016 -Â